

PhenoPath at USCAP 2005 Annual Meeting



PhenoPath at USCAP 2004

PhenoPath Laboratories will be actively participating at this year's 2005 Annual Meeting of the United States and Canadian Academy of Pathology in San Antonio, Texas, February 26th through March 4th, 2005. Pathologists will be presenting posters and platform presentations highlighting

some of the ongoing clinical research studies at PhenoPath Laboratories. PhenoPath will also have an exhibit booth during the meeting, showcasing tests that have been added to our expanding portfolio. Returning once again is our very popular PhenoQuiz! Stop by the PhenoBooth to challenge your IHC & FISH knowledge with our new interactive format.

PHENOPEOPLE PROFILES

This edition highlights our two 2004-2005 IHC Fellows. The IHC Fellowship Program at PhenoPath was established in 2001 and is fully accredited by the ACGME.



Diana Treaba, M.D.
PhenoPath 2004-2005 IHC Fellow

Diana Olga Treaba, M.D., is one of the two current, 2004-2005 IHC Fellows at PhenoPath Laboratories. Diana is originally from Targu-Mures in Romania, where she received her M.D. Diana completed her residency requirements in AP/CP at Rush-Presbyterian St. Luke's Medical Center in Chicago. She then completed a Fellowship in Hematopathology at Northwestern Memorial Hospital and Northwestern University Medical School.

In addition to a number of scholarships Diana has received during her academic years, she has authored several publications appearing in such journals as Diagnostic Cytopathology, Modern Pathology and Acta Cytologica. She has also authored several abstracts, the most recent being presented at USCAP in 2005. Diana passed the Hematology Board Exam in September 2004. Upon completing her fellowship at PhenoPath, she intends to obtain a position in Hematopathology.



Chun Hing Tse, M.D.
PhenoPath 2004-2005 IHC Fellow

Chun Hing (Christopher) Tse, M.D., our second 2004-2005 IHC Fellow, graduated from the Faculty of Medicine at the University of Hong Kong. He completed a one-year internship before going onto pathology training in the Department of Pathology of Queen Elizabeth Hospital, the largest hospital in Hong Kong. Dr. Tse became a member of the Royal College of Pathologists of the United Kingdom (an equivalent of board certification), and then undertook Fellowships in liver pathology and neuromuscular pathology in Scotland. He became a Fellow of the UK College (FRCPath) in 1996.

Christopher entered the field of pathology at a time when pathology was rapidly developing in Hong Kong. He helped build the pathology service at the largest hospital in Hong Kong, with specialists in both anatomic and clinical pathology. Though coming from a busy pathology department, Christopher marvels at the variety and quality of the cases he sees at PhenoPath.

USCAP Presentations by PhenoPath Pathologists

Sunday, February 27th, Fellowship Fair 5-7PM

A PhenoPath representative will be attending the Fellowship Fair to provide detailed information about the Fellowship program at PhenoPath and answer any questions. Applications are currently being accepted for the 2006-2007 Fellowship position at PhenoPath.

Monday, February 28th, Evening Poster Session

Diana Treaba, M.D.; *Significantly Improved Sensitivity for ER Detection in Breast Cancer Using a New Rabbit Monoclonal Anti-ER Antibody (SP1).*

Tuesday, March 1st, Morning Platform Presentation

Diana Treaba, M.D.; *Influence of Demographic and Specimen Related Parameters on EGFR Immunostaining in Colorectal Adenocarcinoma: A Study of 484 Cases.*

Tuesday, March 1st, Morning Poster Session

Allen M. Gown, M.D.; *A New Anti-ER Rabbit Monoclonal Antibody Improves Efficiency of Immunohistochemical Evaluation of ER Status in Breast Cancer.*

Todd S. Barry, M.D., Ph.D.; *High Sensitivity and Specificity of FISH in Routine Detection of t(X;18)(p11.2;q11.2) in Synovial Sarcomas Using Formalin-Fixed Paraffin-Embedded Tissue Sections and Automated Morphometric Image Analysis.*

Todd S. Barry, M.D., Ph.D.; *High Sensitivity and Specificity of FISH in Routine Detection of t(14;18)(q32;q21) and t(11;14)(q13;q32) in Formalin-Fixed Paraffin-Embedded Tissue Sections Using Automated Morphometric Image Analysis.*

Tuesday, March 1st, Evening Poster Session

Allen M. Gown, M.D.; *A Two-Tiered Statistical Analysis-Based Quality Assurance Program for HER-2 Assessment by Immunohistochemistry.*

Thursday, March 3rd, Short Course Presentation

Allen M. Gown, M.D. & Carlos Bacchi, M.D. (Consultoria em Patologia, Botucatu, SP, Brazil); *Diagnostic Immunohistochemistry of Solid Tumors; Strategies and Solutions.* This course will present state-of-the-art diagnostic immunohistochemistry, taking a practical but comprehensive approach utilizing an unknown case format. There will be an introduction highlighting methodological issues and caveats in interpreting immunohistochemical studies, followed by presentations on applications of immunohistochemistry to diagnostic problems in surgical pathology.

QUARTERLY IHC CONFERENCE

In February 2003, PhenoPath Laboratories commenced a series of quarterly evening immunohistochemistry conferences at our facility in the Fremont neighborhood of Seattle. This provides a venue where Seattle-area pathologists can meet regularly on an informal basis, share interesting cases, and learn from each other. The format of the conference is a Social Hour, beginning at 6:00PM, followed by a lecture by an invited speaker at 7:00PM (see below) and concluding with interesting case presentations.

Winter Quarterly Conference



February 17th, 2005, Mary Bronner, M.D., Director of the Gastrointestinal Pathology and its associated Fellowship Program in the Department of Anatomic Pathology at the Cleveland Clinic Foundation in Cleveland, Ohio, will present a talk entitled *Neoplastic Progression in Ulcerative Colitis: From Chromosomes to the Clinic.*

Dr. Bronner is an internationally recognized expert in gastrointestinal and hepatic pathology and has been intimately involved as an investigator on several NIH and industry grants dealing with ulcerative colitis, colorectal and pancreatic cancer, and Barrett's esophagus. She has 13 years of experience directing the diagnostic and research molecular pathology laboratories at the University of Washington and now at the Cleveland Clinic Foundation.

PHENOPATH ROADSHOWS

Be sure to visit us at the following meetings. For more current information visit our website www.phenopath.com.



USCAP 2005 Annual Meeting

February 26th–March 4th, 2005; San Antonio, TX
Please see the USCAP article on the front page.



Society for Applied Immunohistochemistry

March 30th, 2005; New York, NY

Dr. Allen M. Gown will be the featured guest speaker at the Memorial Sloan Kettering Hospital SFAI meeting. He will be presenting two talks: *Update of FISH Analysis of Tumors, using Automated Quantitative Methods*, and *Quantitative ER-PR Analysis: Is it Necessary?*

AACR 2005 Annual Meeting

April 17th–20th, 2005; Anaheim, CA



For the first time, PhenoPath Laboratories will have an exhibition booth at this premier meeting for cancer research, highlighting our Contract Research Services.

Washington State Histology Symposium

April 30th–May 1st, 2005; Seattle, WA



Dr. Allen M. Gown will be presenting a 3-hour workshop during the WSHS Spring Meeting on Sunday, May 1st, 2005. Dr. Gown's workshop will cover *Immunohistochemistry: General Principles and Practical Diagnostic Concerns and Novel Markers of Carcinomas of Unknown Primary* concluding with *Selected Case Presentations Highlighting New Markers*. In addition, PhenoPath will be exhibiting at the WSHS meeting.

RECENT PUBLICATIONS

The following are recent publications by PhenoPath pathologists. If these articles are not available in your medical library, send your request to PhenoPath.

Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO Nuclear beta-catenin in mesenchymal tumors. *Mod Pathol* 18(1):68-74, 2005. Beta catenin is normally found in the cytoplasm but translocates and accumulates in the nucleus when there are abnormalities in the Wnt and E-cadherin signaling pathways. This study suggests that a very restricted subset of the latter

tumors (e.g. solitary fibrous tumor, synovial sarcoma, etc.) show high level nuclear localization of beta catenin, and this may have important clinical diagnostic implications.

Gown AM *Unmasking the mysteries of antigen or epitope retrieval and formalin fixation.* *Am J Clin Pathol* 121:172-174, 2004. This editorial discusses some of the proposed mechanisms of 'antigen retrieval' or 'epitope retrieval' and how it relates to the process of formalin fixation.

Hwang, H, Quenneville L, Yaziji H, Gown AM *Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin.* *Appl Immunohistochem Mol Morphol* 12:122-126, 2004. This paper is the result of studies performed at PhenoPath Laboratories over the past several years concerning the use of WT-1 as a marker of serous ovarian carcinomas.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Van De Rijn M, Perou CM *Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.* *Clin Cancer Res* 10:5367-5374, 2004. This project, performed in conjunction with investigators at the University of British Columbia and Stanford University, is an outgrowth of molecular expression array studies which have suggested the presence of a unique subset of breast cancers referred to as the 'basal-like'; this may be an important subgroup to identify, owing to poor outcome of this subset of breast cancer patients. In this study, the immunophenotype of this subset is described.

Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM *HER-2 testing in breast cancer using parallel tissue-based methods.* *JAMA* 291:1972-1977, 2004. This landmark study performed at PhenoPath Laboratories involving more than 3,000 cases demonstrates high predictive value of 3+ HER2 immunohistochemistry studies for HER2 amplification via fluorescence in situ hybridization, when IHC is performed in the context of an ongoing quality assurance program.

PhenoPath
LABORATORIES

A physician owned and directed national reference pathology laboratory for advanced diagnostic and research services.

Recent News & Information
Now Offering: New Tumor Diagnostic Fluorescent In Situ Hybridization (FISH) Studies for Paraffin Sections

- Synovial Sarcoma t(18)
- PNET/Ewing's Sarcoma t(11;22)
- Follicular Lymphoma t(14;18)
- Mantle Cell Lymphoma t(11;14)
- Molar Pregnancy (Chromosome 17)

Home | Sitemap | Disclaimer | Contact Us | Send Us Specimens
Diagnostic Services | Research Services | About PhenoPath

©2004 PhenoPath Laboratories, PLLC
All Rights Reserved.

Visit our new and improved website at www.phenopath.com